ARIUS Receives Funding from NRC-IRAP

ARIUS Research Inc. (TSX Venture: ARI) 

TORONTO, Sept. 19 /CNW/ - ARIUS Research Inc. (TSX-V: ARI) announced
today that the National Research Council's Industrial Research Assistance
Program (NRC-IRAP) has awarded the company a non-repayable contribution to
support work designed to expand and extend ARIUS' FunctionFIRST(TM) Platform
for generating novel anti-cancer antibodies.
The expanded FunctionFIRST(TM) Platform will be used to produce ARIUS'
next generation of antibodies. It will also enhance and expand ARIUS'
capabilities for pre-clinical antibody pipeline development and contribute to
the characterization of cancer targets.
"We are very pleased to receive approval for this contribution from IRAP
in support of our unique, Canadian antibody development platform," stated Dr.
David S. Young, President and C.S.O. of ARIUS. "Antibodies have emerged as a
major new success in extending the lives of cancer patients. The constant
improvement in our technology will ultimately increase the value of the
antibodies that we produce both for our partners and us. This will ultimately
translate into a greater benefit for patients. IRAP's support will help our
scientists contribute to this critical effort."

About NRC-IRAP

The National Research Council's Industrial Research Assistance Program
(NRC-IRAP) provides a range of both technical and business oriented advisory
services along with potential financial support to growth-oriented Canadian
small and medium-sized enterprises. The program is delivered by an extensive
integrated network of over 230 field staff in 90 communities across the
country. Working directly with these clients, NRC-IRAP supports innovative
research and development and commercialization of new products and services

About ARIUS Research

ARIUS Research Inc. is a biotechnology company dedicated to the discovery
and development of novel anticancer monoclonal antibodies (MAbs). Established
in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM),
that rapidly identifies powerful MAbs targeting a variety of cancer
indications. This antibody generation engine has enabled ARIUS to assemble a
growing pipeline of over 300 functional MAbs, which may be used for commercial
collaborations, out-licensing or in-house development. ARIUS has ongoing
licensing and research partnerships with key biotechnology and drug
development companies that provide revenues and access to external
technologies. The long-term vision of ARIUS is to deliver personalized therapy
by matching multiple antibodies to the distinct antigenic characteristics of
each patient's tumor cells thereby increasing efficacy and avoiding side
effects. ARIUS is listed on the TSX Venture Exchange under the symbol "ARI".

Forward-Looking Statement

Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in the Company's
Annual Report, forthcoming news releases and other filings with Canadian
securities regulatory authorities and the U.S. Securities & Exchange
Commission. Forward-looking statements are based on our current expectations
and ARIUS is not obligated to update such information to reflect later events
or developments.

Website: www.ariusresearch.com

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.